Topics
Glioblastoma | Treatment | Clinical trials | Dendritic-cell-based vaccine
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Dendritic cells
*Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE
2nd, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA,
Friedman AH, Friedman HS, Bigner DD.
An
epidermal growth factor receptor variant III-targeted vaccine is
safe and immunogenic in patients with glioblastoma multiforme.
Mol
Cancer Ther. 2009 Oct 12;8(10):2773-9. doi:
10.1158/1535-7163.MCT-09-0124. PMID:
19825799. Interventional
study. ˍ
Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni
M, Fausti V, Ranallo N, Calpona S, Tazzari M, Petrini M, Granato
AM, Pancisi E, Foca F, D'Allagata M, Bondi I, Amadori E, Cortesi
P, Zani C, Ancarani V, Gamboni A, Polselli A, Pasini G, Bartolini
D, Maimone G, Arpa D, Tosatto L.
First
step results
from a phase II study of a dendritic cell vaccine in glioblastoma
patients (CombiG-vax).
Front
Immunol. 2024 Aug 13;15:1404861. doi:
10.3389/fimmu.2024.1404861. PMID:
39192978. Interventional study. ˍ
*Wong CE, Chang Y, Chen PW, Huang YT, Chang YC, Chiang CH, Wang
LC, Lee PH, Huang CC, Hsu HJ, Lee JS.
Dendritic
cell vaccine for glioblastoma: an updated meta-analysis and trial
sequential analysis.
J
Neurooncol. 2024 Aug 21. doi:
10.1007/s11060-024-04798-w. PMID:
39167243. Meta-analysis˰
ˍ